Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $4.57 Analyst target: $38.50 Upside: 742.45%
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is headquartered in San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.